Long-term complications of nucleoside reverse transcriptase inhibitor therapy
Dieterich, D.T.
Aids Reader 13(4): 176-184; 187
2003
ISSN/ISBN: 1053-0894 PMID: 12741368 Document Number: 560962
HAART has resulted in dramatic declines in morbidity and mortality among patients infected with HIV. Increased experience with HAART has led to the detection of drug related toxicities that may compromise adherence and necessitate discontinuation of treatment and alteration of otherwise effective regimens. This article considers the major long-term complications associated with nucleoside reverse transcriptase inhibitor (NRTI) use--hyperlactatemia and lactic acidosis/hepatic steatosis, other hepatotoxicities, pancreatitis, lipodystrophy, lipoatrophy, neuropathy, and hematologic toxicities. Mechanisms by which NRTIs may produce these effects are discussed, as are differential effects of agents in this class and management options.
Document emailed within 1 workday
Related Documents
Duvivier, C.; Ghosn, J.; Assoumou, L.; Soulié, C.; Peytavin, G.; Calvez, V.; Génin, M.èl.A.é; Molina, J.-M.; Bouchaud, O.; Katlama, C.; Costagliola, D.; Beucler, I.; Dion, E.; Raffi, F.; Delfraissy, J.F.; Commoy, M.J.; Massip, P.; Garraffo, R.; Mazetier, L.; Izopet, J.; Chêne, G.; Racheline, A.; Jarousse, B.; Abgrall, S.; Obenga, G.; Phung, B.; Gerbe, J.; Bentata, M.; Honoré, P.; Rami, A.; Delcey, V.; Drener, M.; Parrinello, M.; Miailhes, P.; Lebouche, B.; Kouadjo, K.; Benmakhlouf, N.; Goujard, C.; Miquel, A.; Quetainmont, Y.; Rannou, M.T.; Perronne, C.; de Truchis, P.; Berthé, H.; Jeantils, V.; Tassi, S.; Rozenbaum, W.; Slama, L.; Chakvetaze, C.; Galanaud, P.; Boué, F.; Delavalle, A.M.; Lefebvre, B.; Bollens, D.; Meynard, J.L.; Oua 2008: Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial Journal of Antimicrobial ChemoTherapy 62(4): 797-808Weidle, P.J.; Moore, D.; Mermin, J.; Buchacz, K.; Were, W.; Downing, R.; Kigozi, A.; Ndazima, V.; Peters, P.; Brooks, J.T. 2008: Liver enzymes improve over twenty-four months of first-line non-nucleoside reverse transcriptase inhibitor-based therapy in rural Uganda Aids Patient Care and Stds 22(10): 787-795
Aurpibul, L.; Puthanakit, T.; Taecharoenkul, S.; Sirisanthana, T.; Sirisanthana, V. 2009: Reversal of growth failure in HIV-infected Thai children treated with non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy Aids Patient Care and Stds 23(12): 1067-1071
Ripamonti, D.; Maggiolo, F. 2008: Rilpivirine, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection Current Opinion in Investigational Drugs 9(8): 899-912
Engchanil, C.; Kosalaraksa, P.; Lulitanond, V.; Lumbiganon, P.; Chantratita, W. 2006: Multi-drug resistant HIV-1 reverse transcriptase genotype in children treated with dual nucleoside reverse transcriptase inhibitors (NRTIs) Journal of the Medical Association of Thailand 89(10): 1713-1720
Mankhatitham, W.; Lueangniyomkul, A.; Manosuthi, W. 2011: Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen Southeast Asian Journal of Tropical Medicine and Public Health 42(3): 651-658
McMahon, J.B.; Buckheit, R.W.; Gulakowski, R.J.; Currens, M.J.; Vistica, D.T.; Shoemaker, R.H.; Stinson, S.F.; Russell, J.D.; Bader, J.P.; Narayanan, V.L.; Schultz, R.J.; Brouwer, W.G.; Felauer, E.E.; Boyd, M.R. 1996: Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor Journal of Pharmacology and Experimental Therapeutics 276(1): 298-305
2000: Non-nucleoside reverse transcriptase inhibitors. First line therapy MMW Fortschritte der Medizin 142(3 Suppl): 34-35
Germanaud, D.; Derache, A.; Traore, M.; Madec, Y.; Toure, S.; Dicko, F.; Coulibaly, H.; Traore, M.; Sylla, M.; Calvez, V.; Marcelin, A.-G. 2010: Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali Journal of Antimicrobial ChemoTherapy 65(1): 118-124
Lalezari, J.P.; DeJesus, E.; Northfelt, D.W.; Richmond, G.; Wolfe, P.; Haubrich, R.; Henry, D.; Powderly, W.; Becker, S.; Thompson, M.; Valentine, F.; Wright, D.; Carlson, M.; Riddler, S.; Haas, F.F.; DeMasi, R.; Sista, P.R.; Salgo, M.; Delehanty, J. 2003: A controlled Phase Ii trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults Antiviral Therapy 8(4): 279-287
Mankhatitham, W.; Luaengniyomkul, A.; Manosuthi, W. 2012: Lipid profile changes in Thai HIV and tuberculosis co-infected patients receiving non-nucleoside reverse transcriptase inhibitors-based antiretroviral therapy Journal of the Medical Association of Thailand 95(2): 163-169
Berezovskaia, I.V.; Chudinov, M.V. 2005: Ester derivatives of nucleoside inhibitors of reverse transcriptase: II. Molecular systems for combined therapy with 3'-azido-3'-deoxythymidine and 2',3'-didehydro-3'-deoxythymidine Bioorganicheskaia Khimiia 31(5): 451-465
Brzezińska, E.; Glinka, R. 2002: Search for new non-nucleoside inhibitors of HIV-1 reverse transcriptase (HIV-1 RT) Acta Poloniae Pharmaceutica 59(5): 379-386
Russo, G.; Paganotti, G.M.; Soeria-Atmadja, S.; Haverkamp, M.; Ramogola-Masire, D.; Vullo, V.; Gustafsson, L.L. 2016: Pharmacogenetics of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in resource-limited settings: Influence on antiretroviral therapy response and concomitant anti-tubercular, antimalarial and contraceptive treatments Infection Genetics and Evolution: Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases 37: 192-207
Puthanakit, T.; Jourdain, G.; Hongsiriwon, S.; Suntarattiwong, P.; Chokephaibulkit, K.; Sirisanthana, V.; Kosalaraksa, P.; Petdachai, W.; Hansudewechakul, R.; Siangphoe, U.; Suwanlerk, T.; Ananworanich, J.; Bunupuradah, T.; Phasomsap, C.; Kaew-on, P.; Kanjanavanit, S.; Hinjiranandana, T.; Layangool, P.; Kamonpakorn, N.; Buranabanjasatean, S.; Ngampiyaskul, C.; Chotpitayasunondh, T.; Chanpradub, S.; Leawsrisuk, P.; Chearskul, S.; Vanprapar, N.; Phongsamart, W.; Lapphra, K.; Chearskul, P.; Wittawatmongkol, O.; Prasitsuebsai, W.; Intalapaporn, K.; Kongstan, N.; Pannin, N.; Maleesatharn, A.; Khumcha, B.; Aurpibul, L.; Wongnum, N.; Nadsasarn, R.; Lumbiganon, P.; Tharnprisan, P.; Udompanich, T.; Yentang, M.; Khonponoi, A.; Maneerat, N.; Denjunta, 2010: HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy HIV Medicine 11(9): 565-572
Wainberg, M.A.; Sawyer, J.P.C.; Montaner, J.S.G.; Murphy, R.L.; Kuritzkes, D.R.; Raffi, F. 2005: Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection Antiviral Therapy 10(1): 13-28
Tarby, C.M. 2004: Recent advances in the development of next generation non-nucleoside reverse transcriptase inhibitors Current Topics in Medicinal Chemistry 4(10): 1045-1057
Lee, B.; Aurpibul, L.; Sirisanthana, V.; Mangklabruks, A.; Sirisanthana, T.; Puthanakit, T. 2009: Low prevalence of insulin resistance among HIV-infected children receiving nonnucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thailand HIV Medicine 10(2): 72-78
Stankov, M.V.; Lücke, T.; Das, A.M.; Schmidt, R.E.; Behrens, G.M.N. 2007: Relationship of mitochondrial DNA depletion and respiratory chain activity in preadipocytes treated with nucleoside reverse transcriptase inhibitors Antiviral Therapy 12(2): 205-216
Flandre, P.; Descamps, D.; Joly, V.; Meiffrédy, V.; Tamalet, C.; Izopet, J.; Aboulker, J-Pierre.; Brun-Vézinet, Fçoise. 2003: Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received Antiviral Therapy 8(1): 65-72